Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol Maintenance in Crohn's Disease
NCT00152425Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2004
- Primary completion
- May 2005
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
A Phase 3 trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Started Feb 2004; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00152425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152425.